
CRISPR Therapeutics (CRSP) Stock Forecast & Price Target
CRISPR Therapeutics (CRSP) Analyst Ratings
Bulls say
CRISPR Therapeutics is positioned positively in the gene editing space, particularly due to its first approved drug, Casgevy, which addresses significant unmet medical needs in sickle-cell disease and transfusion-dependent beta-thalassemia. The revitalization of large-cap pharma interest in gene editing platforms, as evidenced by recent acquisitions and clinical advancements from competitors, underscores a growing market potential for CRISPR's innovative technology across various therapeutic areas, including immuno-oncology and cardiometabolic diseases. The company's strategy of targeting well-validated diseases and exploring additional applications of its CRISPR/Cas9 platform supports a favorable outlook on its long-term growth prospects and market positioning.
Bears say
The analysis reflects a negative outlook for CRISPR Therapeutics, primarily based on the assumption that sales of its approved drug, Casgevy, may not accelerate as anticipated, leading to a potential 30% downside from the company's base case valuation. Key risks highlighted include delays in advancing critical drug candidates through trials, with only a 30% probability of approval for CTX112 and a mere 20% for both CTX320 and CTX310, alongside concerns over generating favorable clinical data. Additionally, the prospect of long-term dilution and challenges in demonstrating the safety and efficacy of several drug candidates, such as CTX112 and CTX320, exacerbate the uncertainty surrounding the company's financial future.
This aggregate rating is based on analysts' research of CRISPR Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
CRISPR Therapeutics (CRSP) Analyst Forecast & Price Prediction
Start investing in CRISPR Therapeutics (CRSP)
Order type
Buy in
Order amount
Est. shares
0 shares